Profile
CYCC VRTX REGN ALNY SGEN ARGX
Company Name Cyclacel Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $11.74M $117.98B $59.32B $43.28B $43.15B $40.50B
Employees 0.01K 6.10K 15.16K 2.23K 3.26K 1.60K
CEO Sing Ee Wong Reshma Kewalramani FASN, Leonard S. Schleifer Yvonne L. Greenstreet David R. Epstein Timothy Van Hauwermeiren EMBA,
Ratings
CYCC VRTX REGN ALNY SGEN ARGX
Quant Rating Score 2 2 4 1 3 4
Quant Rating Sell Sell Buy Strong Sell Neutral Buy
Trading
CYCC VRTX REGN ALNY SGEN ARGX
Last Close $8.78 $366.54 $563 $438.93 $228.74 $661.83
High 52 $17.15 $516.74 $1201.76 $438.93 $228.74 $690.32
Low 52 $0.19 $366.54 $482.92 $224.58 $228.74 $514.23
Price vs. 52 Week High -48.8 % -29.07 % -53.15 % 0 % 0 % -4.13 %
Price vs. 52 Week Low 4521.05 % 0 % 16.58 % 95.44 % 0 % 28.7 %
Total Return
CYCC VRTX REGN ALNY SGEN ARGX
1 Month Return 135.39 % -23.47 % 1.9 % 36.86 % 0 % 19.21 %
3 Month Return 3364.88 % -13.75 % 6.67 % 74.77 % 0 % 20.41 %
6 Month Return 2713.2 % -21.9 % -20.65 % 58.92 % 0 % 2.35 %
9 Month Return 1725.36 % -29.07 % -32.04 % 58.21 % 0 % 11.05 %
YTD Return 2235.11 % -8.98 % -20.96 % 86.53 % 0 % 7.61 %
1 Year Return 518.31 % -21.75 % -50.23 % 62.86 % 0 % 23.71 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CYCC VRTX REGN ALNY SGEN ARGX
Dividend Yield Percentage (TTM) 2.02 % - 0.31 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - -3.53 % 4.37 % -1.49 % -5.87 % -44.32 %
Dividend Per Share (TTM) 0.15 % - 1.76 % - - -
Payout Ratio (TTM) - - 4.18 % - - -
Growth
CYCC VRTX REGN ALNY SGEN ARGX
Asset Growth -53.5 % -0.87 % 14.15 % 10.71 % -1.21 % 36.55 %
Gross Profit Growth -91.19 % 10.25 % 8.23 % 26.81 % 22.93 % 77.08 %
Revenue Growth -89.76 % 11.66 % 8.27 % 22.97 % 24.65 % 78.6 %
Revenue 3 Year - 45.6 % -13.44 % 147.1 % 91.56 % 275.84 %
Revenue 5 Year - 163.93 % 82.78 % 775.72 % 215.48 % 1701.04 %
Revenue 10 Year -99.97 % 1632.15 % 429.43 % 2487.4 % 494.04 % 5950.81 %
EBIT Growth 52.84 % -93.69 % 13.17 % 24.59 % - 128.87 %
Net Income Growth 50.29 % -114.8 % 11.61 % 36.82 % 9.51 % 382.34 %
Net Income 3 Yeari Growth Per Share 95.75 % -122.89 % -46.47 % 69.73 % -763.59 % 274.39 %
Net Income 5 Yeari Growth Per Share 85.93 % -145.38 % 111.07 % 73.13 % -276.93 % 396.61 %
Net Income 10 Yeari Growth Per Share 99.36 % 33.84 % 1232.49 % 55.09 % -624.16 % 938.02 %
Operating Income Growth 52.84 % -106.08 % -1.39 % 37.31 % 10.13 % 94.91 %
Operating Cash Flow Growth (CFG) 50.41 % -113.93 % -3.78 % -107.98 % 9.07 % 80.31 %
Operating 3 Year CFG 96.91 % -118.65 % -38.85 % 98.8 % -147.99 % 88.36 %
Operating 5 Year CFG 91.69 % -131.3 % 84.11 % 97.44 % -195.86 % -135.21 %
Operating 10 Year CFG 99.53 % 12.43 % 517.51 % 97.08 % -2622.09 % -64 %
EPS Growth 95.27 % -114.8 % 10.39 % 38.64 % 10.81 % 369.77 %
EPS Diluted Growth 95.27 % -114.97 % 10.27 % 38.64 % 10.81 % 347.67 %
Book Value Per Share -134.4 % -6.59 % 11.76 % 129.75 % -9.83 % 28.16 %
Share Holder 3 Year Equity Growth Per Share -100.41 % 62.6 % 53.21 % -89.42 % 33.72 % 85.14 %
Share Holder 5 Year Equity Growth Per Share -101.83 % 168.85 % 167.88 % -96.01 % 220.81 % 200.53 %
Share Holder 10 Year Equity Growth Per Share -100.11 % 1265.7 % 1113.59 % -95.83 % 691.19 % 1039.11 %
Dividend Per Share Growth -100 % - - - - -
Dividend 3 Year Growth Per Share -100 % - - - - -
Dividend 5 Year Growth Per Share -100 % - - - - -
Dividend 10 Year Growth Per Share -100 % - - - - -
Debt Growth -100 % 116.42 % 0.06 % 2.27 % -23.28 % 95.27 %
Free Cash Flow Growth 50.43 % -124.1 % -0.08 % -201.54 % 3.67 % 67.46 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2022 31 Dec 2024
Profitability
CYCC VRTX REGN ALNY SGEN ARGX
Gross Profit Margin TTM 128.57 % 86.03 % 87.44 % 86.01 % 79.1 % 65.32 %
Return on Assets TTM -223.54 % -4.32 % 11.67 % -6.4 % -16.61 % 15.06 %
Return on Equity TTM -3641 % -6.25 % 14.43 % -509.33 % -20.8 % 18.96 %
Return on Capital Employed TTM -413.06 % -3.89 % 11.12 % -3.68 % -21.46 % 5.04 %
Net Income Per EBT TTM 107.36 % 329.41 % 91.46 % 75.89 % 101.33 % 237.3 %
EBT Per Ebit TTM 61.29 % 40.44 % 126.92 % 308.03 % 98.26 % 147.38 %
EBIT Per Revenue TTM 60404.76 % -6.69 % 27.02 % -4.91 % -31.24 % 13.47 %
Cash Flow To Debt Ratio TTM -83447.19 % -59.44 % 175.35 % -3.47 % -1043.73 % -175.92 %
Receivables Turnover TTM - 6.15 2.53 5.62 3.91 1.91
Payables Turnover TTM 0.05 3.49 2.47 3.37 1.97 0.88
Inventory Turnover TTM - 1.14 0.56 5.01 0.96 2.21
Fixed Asset Turnover TTM -105 % 421.34 % 293.64 % 337.41 % 665.41 % 5009.77 %
Asset Turnover TTM -0.56 % 48.51 % 37.19 % 55.72 % 53.41 % 31.97 %
Operating Cash Flow Per Share TTM -0.58 -3.82 45.13 -0.35 -2.46 -1.07
Free Cash Flow Per Share TTM -0.58 -4.9 36.58 -0.58 -2.88 -1.09
Cash Per Share TTM 26.62 % 2413.86 % 7107.14 % 2024.29 % 939.52 % 5536.58 %
Operating Cash Flow Sales Ratio TTM 35763.08 % -8.83 % 33.37 % -1.92 % -23.12 % -3.31 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 128.33 % 81.05 % 167.11 % 117.04 % 102.26 %
Cash Flow Coverage Ratios TTM -83447.19 % -59.44 % 175.35 % -3.47 % -1043.73 % -175.92 %
Price To Free Cash Flows Ratio TTM -1.56 -93.78 15.43 -574.08 -81.26 -521.84
Price To Operating Cash Flows Ratio TTM -12.79 -120.39 12.38 -954.11 -93.1 -618.62
Price Cash Flow Ratio TTM -12.79 -120.39 12.38 -954.11 -93.1 -618.62
Income Statement (TTM)
CYCC VRTX REGN ALNY SGEN ARGX
Revenue $0B $11.02B $14.2B $2.25B $1.96B $2.19B
Gross Profit $0B $9.49B $11.75B $1.92B $1.55B $1.96B
Gross Profit Ratio 86.05% 86.11% 82.74% 85.62% 79.1% 89.62%
EBITDA $-0.01B $0.49B $5.32B $-0.18B $-0.62B $0.11B
Net Income $-0.01B $-0.54B $4.41B $-0.28B $-0.61B $0.83B
EPS Diluted -1.36 -2.08 38.34 -2.16 -3.3 12.78
Balance Sheet (MRQ)
CYCC VRTX REGN ALNY SGEN ARGX
Long Term Debt $0B $1.66B $2.7B $1.25B $0.04B $0.03B
Total Liabilities $0.01B $6.12B $8.41B $4.17B $0.87B $0.7B
Total Equity $-0B $16.41B $29.35B $0.07B $2.8B $5.5B
Total Investments $0B $6.65B $15.42B $1.73B $1.42B $1.93B
Total Debt $0B $1.75B $2.7B $1.3B $0.04B $0.04B
Total Assets $0B $22.53B $37.76B $4.24B $3.67B $6.2B
Cash Flow Statement (TTM)
CYCC VRTX REGN ALNY SGEN ARGX
Net Income $-0.01B $-0.54B $4.41B $-0.28B $-0.61B $0.83B
Inventory $0B $-0.52B $-0.62B $0.01B $-0.23B $-0.1B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $4.42B $-0.01B $-0.45B $-0.08B
Capital Expenditure $0B $-0.3B $-0.76B $-0.03B $-0.08B $-0.07B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 41.95
AARD Aardvark Therapeutics, Inc. Common Stock 11.99
ABCL AbCellera Biologics Inc. 4.25
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 6.26
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.36
ABPWW 0.0368
ABSI Absci Corporation 2.84
ABUS Arbutus Biopharma Corporation 3.4
ABVC ABVC BioPharma, Inc. 2.7
ABVX Abivax SA American Depositary Shares 70.13
ACAD ACADIA Pharmaceuticals Inc. 24.6
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.621
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.5
ACIU AC Immune SA 2.14
ETFs With Exposure to CYCC
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 139.02
VXF Vanguard Extended Market Index Fund 0 196.6
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 149.14
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 149.15
VEMPX Vanguard Extended Market Index InstlPlus 0 368.04
Unlock